Latest research on Celecoxib

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Celecoxib indications

Celecoxib, a cyclooxygenase 2 (COX2) inhibitor, was effective in the tgSODG93A, but not in patients [50]. [source, 2016]
Tat-SOD solution was topically administered to the shaven backs of mice with Celecoxib (a COX-2 inhibitor) or PTIO (an SNP antagonist) for 30 min; then, animals were treated with SNP (an NO donor) for 4 h to test the protective effect. [source, 2016]
The pigment tone was significantly and dose-dependently attenuated by Tat-SOD and Celecoxib, indicating that Tat-SOD effectively reduced SNP-induced COX-2 production as well as did Celecoxib in mouse skin. [source, 2016]
To confirm these effects, the Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) was conducted to test whether chondroitin sulfate plus glucosamine hydrochloride has comparable efficacy to Celecoxib after 6 months of treatment in patients with painful knee osteoarthritis. [source, 2016]
We have also reported that, in vitro, the anti-inflammatory drug, Celecoxib, can specifically induce EC AMPK phosphorylation,34 while at supra-therapeutic concentrations, Metformin has a similar effect. [source, 2016]
As shown in Figure 1B, Celecoxib effectively reduced the production of progeny virion with a 50% inhibitory concentration (IC50) of 2.34 µM. [source, 2015]
To determine whether the inhibitory effect of Celecoxib on KSHV lytic replication is due to the loss of latent KSHV episomes, BCBL-1 cells were exposed to Celecoxib in the absent of TPA induction, and 72 h post-treatment, the KSHV copy numbers in cells was determined by qPCR. [source, 2015]
Western blotting and indirect immunofluorescence assay revealed that Celecoxib treatment had no appreciable effect on this protein (Figure 1E,F), further indicating that Celecoxib has a disproportionate impact on KSHV lytic replication compared to KSHV latency under our experimental conditions. [source, 2015]
Taken together, our results indicate that the antiviral activity of Celecoxib is independent of COX-2 inhibition, and may be an off-target effect via a COX-2-independent mechanism. [source, 2015]
To identify the stages targeted by Celecoxib during viral replication, iSLK.219 cells were used to determine the effect of Celecoxib on the stages of KSHV reactivation, DNA replication and virion production. iSLK.219 cells harbor the rKSHV.219 virus that encodes green fluorescent protein (GFP) under control of the elongation factor 1α promoter (EF-1α) and contain a PAN promoter-driven RFP reporter [26,27]. [source, 2015]